阿加曲班治疗急性脑梗死对患者神经功能障碍程度以及生活能力的影响  

Effect of argatroban on the degree of neurological dysfunction and life ability in patients with acute cerebral infarction

作　　者：郑艳[1] 蒋辉[1] ZHENG Yan;JIANG Hui(The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine,Nanjing 210029,Jiangsu,China)

机构地区：[1]南京中医药大学附属医院,江苏南京210029

出　　处：《现代中西医结合杂志》2018年第28期3113-3116,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的探讨阿加曲班加抗血小板聚集药物与双抗治疗急性脑梗死的临床疗效及安全性。方法选择206例临床确诊为急性脑梗死的患者,根据患者意向分为2组,其中实验组103例给予阿加曲班加阿司匹林或氯吡格雷治疗,对照组103例接受阿司匹林联合氯吡格雷双抗治疗。采用NIHSS评分评估治疗前和治疗7,14,30,90 d时2组患者神经功能障碍程度,使用日常生活能力量表中的Barthel指数评估治疗14,30,90 d时2组神经功能障碍康复程度,并于90 d时使用mRS进行综合生活能力评估。结果 2组治疗后NIHSS评分均显著降低(P均<0. 05),实验组治疗7,14,30 d时NIHSS评分均显著低于对照组(P均<0. 05),但90 d时治疗效果无明显差异(P> 0. 05)。治疗14,30 d实验组Barthel指数均显著高于对照组(P均<0. 05),而90 d时无明显差异(P> 0. 05);治疗后90 d时实验组mRS评分略低于对照组,但差异无统计学意义(P> 0. 05)。2组药物均安全性良好,无严重不良反应。结论阿加曲班可抑制病情进展,改善神经功能缺损症状,具有良好的安全性。Objective It is to investigate the clinical efficacy and safety of argatroban plus antiplatelet aggregation drug and dual antiplatelet therapy in the treatment of acute cerebral infarction. Methods A total of 206 patients with clinically diagnosed acute cerebral infarction were enrolled and divided into two groups according to the patient＇s intention. Among them, the test group including 103 patients was treated with argatroban plus aspirin or clopidogrel, and the control group including 103 patients was treated with aspirin plus clopidogrel for dual antiplatelet therapy. The NIHSS score was used to evaluate the degree of neurological dysfunction in the two groups before treatment and after treatment for 7, 14, 30, and 90 days. The Barthel index in the daily living ability scale was used to evaluate the rehabilitation of two groups of neurological dysfunction after treatment for 14, 30, and 90 days, mRS was used to evaluated comprehensive life ability after treatment for 90 days. Results The NIHSS scores of the two groups were significantly decreased after treatment （ P 〈0.05）, the NIHSS scores of the test group were significantly lower than those of the control group after treatment for 7, 14 and 30 days （ P 〈0.05）, but there was no significant difference in the treatment effect between the two groups after treatment for 90 days （ P 〉0.05）. The Barthel index of the test group was significantly higher than that of the control group at 14 and 30 days after treatment （ P 〈0.05）, but there was no significant difference at 90 days （ P 〉0.05）. At the 90th day after treatment, the mRS score of the experimental group was slightly lower than that of the control group, however, the difference was not statistically significant （ P 〉0.05）. All the drugs used in the two groups were safe and had no serious adverse reactions. Conclusion Argatroban can inhibit the progression of the disease, improve the symptoms of neurological deficits, and has good safety in the treatment of acute cerebra

关 键 词：急性脑梗死 阿加曲班 双抗 预后 

分 类 号：R743.33[医药卫生—神经病学与精神病学]